CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@broadcastmed.com.

Kathryn Ciccolini, AGACNP-BC, DNP, MSN, OCN

CAR T-Cell Therapy Resource Center

Megan Spychalla, PA-C: Developing a Successful CAR T-Cell Therapy Outpatient Program—Behind the Scenes at the Mayo Clinic

ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

CAR T-Cell Therapy for Large B-Cell Lymphoma

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

The Lancet Oncology

Fractionated initial infusion and booster dose of ARI0002h, a humanised BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): A single-arm, multicentre academic pilot study

JAMA Network

CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome

New England Journal of Medicine

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

British Journal of Haematology

Severe persistent neurotoxicity associated with CAR T therapy in children

New England Journal of Medicine

Survival with axicabtagene ciloleucel in large B-cell lymphoma

Lancet

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label single-arm, phase 1-2 study

British Journal of Haematology

Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

ASGCT Abstract

First in human studies show activation of SC-DARIC33, a rapamycin-regulated anti-CD33 CAR T cell therapy, in patients with AML

Lancet

The denominator in early phase CAR T-cell trials examining novel taret antigens

British Journal of Haematology

Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Neurologic Toxicity Post-CAR T-Cell Therapy and CRS: Differentiating Symptoms and Individual Management

Fast Facts #12: BCMA Targets